Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinopharm Group CoSHTDF -6.74%76 Intrinsic Value: Projected FCF is $8.18 as of Jul. 31, 2026, which is 2306% above its 10-year median of 0.34. GuruFocus rates SHTDF with a GF Score™ of 76/100 and a GF Value™ of $2.58 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 74 Medical Distribution companies, Sinopharm Group Co ranks better than 93.24% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-07-31), Sinopharm Group Co's Intrinsic Value: Projected FCF is $8.18. The stock price of Sinopharm Group Co is $2.133. Therefore, Sinopharm Group Co's Price-to-Intrinsic-Value-Projected-FCF of today is 0.3.
The historical rank and industry rank for Sinopharm Group Co's Intrinsic Value: Projected FCF or its related term are showing as below:
SHTDF'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.26 Med: 0.34 Max: 0.88
Current: 0.26
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Sinopharm Group Co was 0.88. The lowest was 0.26. And the median was 0.34.
SHTDF's Price-to-Projected-FCF is ranked better than 93.24% of 74
companies
in the Medical Distribution industry
Industry Median: 0.79
vs SHTDF: 0.26
Sinopharm Group Co (OTCPK:SHTDF) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Sinopharm Group Co's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
2.133
/
8.5640989701033
=
0.25
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co Intrinsic Value: Projected FCF Related Terms
Sinopharm Group Co Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co Intrinsic Value: Projected FCF Chart
SHTDF vs MCK, COR, CAH: Intrinsic Value: Projected FCF Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co Price-to-Projected-FCF vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Price-to-Projected-FCF falls into.
Sinopharm Group Co Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $8.18 mean?
Sinopharm Group Co (SHTDF) has a Intrinsic Value: Projected FCF of $8.18 as of Jul. 31, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Sinopharm Group Co and its competitors. This is 2306% above median its historical median of 0.34. Over the past decade, Sinopharm Group Co's Intrinsic Value: Projected FCF has ranged from 0.26 to 0.88. According to the industry distribution chart, Sinopharm Group Co ranks #5 out of 74 companies in the Medical Distribution industry, placing it in the top 6.8%.
Is Sinopharm Group Co's Intrinsic Value: Projected FCF too high?
Sinopharm Group Co's current Intrinsic Value: Projected FCF of $8.18 is 2306% above median its 10-year median of 0.34. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 0.88. The Medical Distribution industry median Intrinsic Value: Projected FCF is 0.79. Sinopharm Group Co's value of $8.18 is 935.4% above this industry median. Based on the distribution chart, Sinopharm Group Co ranks #5 out of 74 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sinopharm Group Co has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Intrinsic Value: Projected FCF compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #5 out of 74 companies for Intrinsic Value: Projected FCF. This places Sinopharm Group Co in the top 7% of its industry — outperforming the majority of peers. The industry median Intrinsic Value: Projected FCF is 0.79. Sinopharm Group Co's value of $8.18 is 935.4% above this benchmark. Historically, Sinopharm Group Co's own Intrinsic Value: Projected FCF has ranged from 0.26 to 0.88 over the past decade. While the company's 10-year median is 0.34 vs. the industry median of 0.79, Sinopharm Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Distribution company?
The median Intrinsic Value: Projected FCF among Medical Distribution companies is 0.79, based on 74 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current Intrinsic Value: Projected FCF of $8.18 is 935.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median Intrinsic Value: Projected FCF is 0.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current Intrinsic Value: Projected FCF is $8.18, which is 2306% above median its own 10-year median of 0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.58, compared to a current price of $2.13 — trading 17.3% below its estimated fair value. The current Intrinsic Value: Projected FCF is $8.18, which is 2306% above median its 10-year median of 0.34 and 935.4% above the Medical Distribution industry median of 0.79. Sinopharm Group Co's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current Intrinsic Value: Projected FCF is $8.18 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.13 is trading 17.3% below its estimated GF Value™ of $2.58.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
Intrinsic Value: Projected FCF: $8.18 (2306% above median its 10-year median of 0.34)
GF Value™: $2.58 vs. price of $2.13 (17.3% below fair value)
Industry Position: 935.4% above the Medical Distribution median (#5 of 74)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
76GF Score
Get the complete analysis for SHTDF
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
